ISBT Awards and Prizes
This page displays information on all ISBT awards, prizes and fellowships.
Please click on the title below to read more about procedures, regulations and previous winners.
Jean Julliard Prize
Information about the Jean Julliard Prize
The Jean Julliard Prize recognises clinicians or scientists who are under 40 years of age and have a noteworthy portfolio of recent published work contributing to advances in transfusion medicine. Individual members of ISBT may self-nominate for the Jean Julliard Prize. The Prize is awarded every two years at the International Congress.
The prize of € 5,000 is open to members and nonmembers of the Society under the age of 40. The Prize is awarded during the next International congress of the ISBT. The successful candidates are required to give a presentation on their submission during the Congress. Travel, registration, and accommodation costs for the congress will be covered by ISBT. Candidates should submit their application through the below online application form.
Regulations for the Jean Julliard Prize
Winners of the Jean Julliard Prize
Recipient of the Jean Julliard Prize
2022
Alexander Vlaar
ISBT Award for Developing Countries
Information about the ISBT Award for Developing Countries
The ISBT Award for Developing Countries is awarded to a Blood Service/Centre or a Department of Transfusion medicine within a medical institution from a Developing Country that has made a significant contribution in strengthening Blood Transfusion Practice within the Country. Qualifying developing countries will be those that are considered low or lower middle income according to the World Bank index.
The Award is in the form of full sponsorship for two delegates from the winning institution to attend an International Congress of the ISBT (airfares, registration, accommodation and per diem). The award also includes sponsorship of an education symposium in the country of the winning applicant (value €10,000). The Award winner will be presented with a certificate at the Opening Ceremony of the International Congress and will be expected to give a presentation in one of the scientific sessions.
The Developing Countries Award 2022 will be presented at the ISBT 2022 virtual congress 4-8 June 2022.
Applications for the 2024 award will open in September 2023.
Recipients of the Award
2022
The winner of the Developing Country Award is the Kasturba Hospital Blood Centre New Delhi, India.
Previous winners
ISBT Award
Information
The ISBT Award will be granted to a person or an organisation that contributes or has contributed in an outstanding way to the education of blood transfusion or transfusion medicine science. The selection of the Award winner(s) and the granting of this Award is a prerogative of the Executive Committee of ISBT.
Recipients of the ISBT Award
Dana Devine
Dana Devine is currently the Chief Medical & Scientific Officer at Canadian Blood Services. She is also Professor of Pathology and Laboratory Medicine at the University of British Columbia, and a founding member of the University’s Centre for Blood Research. She was the Editor-in-Chief of ISBT's blood transfusion journal Vox Sanguinis. Dr. Devine completed her research training at Duke University in North Carolina where she obtained the Ph.D. degree. She has a longstanding research career in blood products, transfusion medicine, platelet biology, complement biochemistry, and coagulation.
Dana leads the Medical Services & Innovation division at Canadian Blood Services. This includes responsibility for transfusion medicine, donor and transplantation services, emerging pathogens and infectious diseases, surveillance and epidemiology, as well as research and development.
Since joining Canadian Blood Services in 1999 as the executive director of research and development, she has played an integral role in a number of initiatives, particularly the development of the visionary Network Clinic for Advancement and Development Laboratory in Vancouver.
Dana holds a PhD in immunology from Duke University in North Carolina, and has more than 25 years of professional association with the University of British Columbia’s Faculty of Medicine as an educator and mentor in blood research.
Peter Flanagan
Peter currently works as a Transfusion Medicine Specialist with New Zealand Blood Service based in Wellington having previously been the National Medical Director of NZBS for over 20 years. He has been closely involved with ISBT as a Board member from 2006, and subsequently President between 2012 and 2014. He chaired the Standing Committee on Ethics from 2016 until 2022 and played a key role in the development of the updated ISBT Code of Ethics. He has been the President of the Australian and New Zealand Society of Blood Transfusion (ANZSBT), is a member of the WHO Expert Panel on Blood Transfusion and has also been closely involved with transfusion activities with the European Directorate for the Quality of Medicines (EDQM) and Council of Europe for 20 years.
ISBT Presidential Award
Information
The Foundation Transfusion Medicine grants this Award to a senior person who has made eminent contributions to transfusion medicine or a related field through original basic or applied research, the practice of transfusion therapy or through significant educational and/or service contribution to the field.
A short curriculum vitae of the proposed candidate and a description of his/her contribution in transfusion medicine, accompanied with three signatures of ISBT members who support the nomination, should be sent to the Secretary- General of the Foundation, Henk Reesink.
The Nomination Committee (consisting of the ISBT President, the ISBT President-Elect, the ISBT Scientific Officer, the Chairman and a member of Board of the Foundation Transfusion Medicine) will decide which candidate will be nominated.
The ISBT Presidential Award is presented every two years at the International Congress of the ISBT.
Recipients of the ISBT Presidential Award
Anneke Brand
Anneke Brand, Professor in Haematology and Transfusion Medicine, passed away Sunday 21 November 2021 at the age of 75. She was a pioneer in both the immunological and the clinical aspects of blood transfusion. Her research led to the universal leukocyte-reduction of all cellular blood components in many countries. She further studied transfusion-related immunomodulation (TRIM), which had a beneficial effect on the outcome of kidney transplantation. In the 1970s she developed a laboratory test to select suitable blood donors for patients with HLA antibodies. She established a registry of blood donors that are homozygous for certain HLA alleles and studied the clinical effect of HLA-matched platelets. In 2000 she was the first to become a professor of Transfusion Medicine in Leiden. As promotor and co-promotor, she supervised over 20 PhD students and co-authored more than 350 papers. She received numerous awards for her contributions to the field, including the ISBT Presidential Award in 2020 and the Landsteiner Award in 2021.
She had a tremendous scientific drive and encyclopedic up-to-date knowledge in many fields of medicine, was well-respected by her colleagues and was adored by her patients.
She will be deeply missed.
Michael Busch
President (2022-2024)
Michael Busch earned his MD and PhD degrees at the University of Southern California followed by residency training in Pathology, Laboratory Medicine and Transfusion Medicine at the University of California, San Francisco (UCSF). He is currently Director of Vitalant Research Institute (VRI) and Senior Vice President for Research and Scientific Affairs at Vitalant, a national network of blood centers and donor testing laboratories. He is also a Professor of Laboratory Medicine at UCSF. Michael is one of the world’s leading transfusion medicine scientists, well-regarded for his ground-breaking work in such transfusion-transmitted diseases as HIV, HBV, HCV, HTLV and West Nile virus and protection of the nation’s blood supply from these and other emerging pathogens including ZIKV and SARS-CoV-2. He has published over 550 peer-reviewed scientific articles, editorials and book chapters. Michael is a member of the Transfusion Transmitted Diseases Committee of AABB, the Research and Development Advisory Committee of Canadian Blood Services and several World Health Organization panels.
Harvey G. Klein
Dr. Klein is Scientist Emeritus at the U.S. National Institutes of Health. For more than 40 years he served as Chief, Department of Transfusion Medicine at the Clinical Center of the National Institutes of Health. Following graduation from Harvard College, Dr. Klein received his doctor of medicine from the Johns Hopkins School of Medicine and completed both his residency and hematology fellowship at Johns Hopkins where he remains Adjunct Professor of Medicine and Pathology.
Dr. Klein has authored or co-authored more than 300 publications pertaining to blood transfusion. He co-authored two editions of Mollison’s Blood Transfusion in Clinical Medicine, often referred to as the “gold standard” textbook in this discipline and has served as editor-in-chief of the Journal of Clinical Apheresis, Associate Editor of Biologicals, and on the editorial board of Blood. He is currently an editor of Transfusion and The Journal of Translational Medicine.
Dr. Klein has been Chair of the US Pharmacopoeia Blood and Blood products Committee, and currently chairs the American National Red Cross Medical Advisory Council. He is a former Council President of the National Marrow Donor Program and Past President of the American Association of Blood Banks. He is a charter member of the US Secretary’s Advisory Committee on Blood Safety and Availability. Dr. Klein has received numerous honors, including the NIH Director’s Award, the Presidential Award of the International Society of Blood Transfusion for lifetime contributions to Transfusion Medicine, and the Fantus Medal, the foremost recognition of
the AABB. The Public Health Service has awarded Dr. Klein the Commendation Medal, the Meritorious Service Medal, and the Secretary’s Distinguished Service Award, the highest civilian award given by the U.S. Department of Health and Human Services.
Dennis Lo
Dennis Lo is the Director of the Li Ka Shing Institute of Health Sciences, the Li Ka Shing Professor of Medicine and Professor of Chemical Pathology of The Chinese University of Hong Kong (CUHK). He is also the Associate Dean (Research) of the Faculty of Medicine of CUHK. Dennis Lo received his Bachelor of Arts degree from the University of Cambridge and the Doctor of Medicine and Doctor of Philosophy degrees from the University of Oxford.
Following his training at Oxford, he was appointed as the University Lecturer in Clinical Biochemistry and Honorary Consultant Chemical Pathologist at the John Radcliffe Hospital, the teaching hospital of the University of Oxford Clinical School. He was also a Fellow at Green College, Oxford.
Dennis Lo returned to Hong Kong in 1997. In the same year, he discovered the presence of fetal DNA in maternal plasma. His group has since remained at the forefront of this field. His group was the first to report the presence of cell-free fetal RNA and fetal epigenetic markers in maternal plasma and pioneered the use of such markers for noninvasive prenatal diagnosis. Dennis Lo and his colleagues were also the first to show that cell-free fetal nucleic acids in maternal plasma could be used for the noninvasive prenatal diagnosis of fetal trisomy 21 and had devised multiple solutions for this hitherto difficult diagnostic problem, including methods based on plasma RNA-SNP allelic ratios, plasma epigenetic markers, digital PCR and massively parallel DNA sequencing. With the use of massively parallel sequencing and the development of novel bioinformatics strategies, Dennis Lo's group succeeded at deciphering a genome-wide genetic map of the fetus through the analysis of the small amounts of fragmented DNA floating in the blood of pregnant women. This scientific achievement lays the foundation for developing non-invasive prenatal diagnostic tests for multiple genetic diseases in a non-invasive way.
In the area of cancer detection, Dennis Lo has pioneered a number of approaches to cancer liquid biopsy, especially for the detection of nasopharyngeal carcinoma and genomewide approaches for screening multiple types of cancer.
In recognition of his work, Dennis Lo has been the recipient of numerous awards, including the King Faisal International Prize in Medicine in 2014, the Future Science Prize - Life Science Prize in 2016 and the 2021 Breakthrough Prize in Life Sciences. He was elected as a Fellow of the Royal Society in 2011, as a Foreign Associate of the US National Academy of Sciences in 2013 and as a Founding Member of the Academy of Sciences of Hong Kong in 2015.
Robert Harry Purcell
Robert Purcell joined the U.S. Epidemic Intelligence Service in 1963, where he investigated respiratory viruses and mycoplasma. He then moved to the National Institute of Allergy and Infectious Diseases, where he rose to chief of the hepatitis viruses section of the Laboratory of Infectious Disease, and co-chief of the Laboratory of Infectious Disease with Brian R. Murphy. He retired from the National Institute of Allergy and Infectious Diseases in 2013.
Purcell was elected to the U.S. National Academy of Sciences in 1988. In 1998, he was granted the King Faisal Prize along with John L. Gerin for "Control of Communicable Diseases".
Robert Purcell is known for his extensive work on hepatitis viruses. In 1972, he was involved in the group that developed the first animal model for hepatitis B. In 1973, Purcell, Albert Kapikian, and Stephen Feinstone discovered and characterized hepatitis A virus. In 1978, Purcell showed that hepatitis C virus is transmissible through blood, and that it remains in the body for life. In the early 1980s, Purcell's group discovered a fourth hepatitis virus, hepatitis D virus. In the 1990s, they discovered Hepatitis E virus. Purcell also helped to develop the first licensed vaccine against hepatitis A virus, and was also involved in developing a vaccine against hepatitis B and D viruses, and a vaccine candidate for protection from hepatitis E virus.
The same team who co-identified the Hepatitis A virus (HAV) developed the first assays that could measure the virus antigen and antibody, and using those assays, the group along with Harvey J. Alter demonstrated through the serologic exclusion of Hepatitis A and Hepatitis B that a third, previously unrecognised form of viral hepatitis existed, originally named non-A, non-B hepatitis (NANBH). Michael Houghton's laboratory at Chiron Corporation ultimately identified the agent associated with NANBH, now known as Hepatitis C, in 1989.
Harvey J. Alter
Dr. Alter earned his medical degree at the University of Rochester Medical School, and trained in internal medicine at Strong Memorial Hospital and at the University Hospitals of Seattle. In 1961, he came to the National Institutes of Health as a clinical associate. He then spent several years with Georgetown University, returning to NIH in 1969 to join the Clinical Center's Department of Transfusion Medicine as a senior investigator, becoming Chief of the Clinical Studies and Associate Director of Research in the Department of Transfusion Medicine at the NIH Clinical Center. In 2000, Alter was awarded the prestigious Clinical Lasker Award. In 2002, he became the first Clinical Center scientist elected to the National Academy of Sciences (NAS), and in that same year he was elected to the Institute of Medicine. Only a small number of scientists nationally are elected to both of these scientific societies.
Dr. Alter has won the 2020 Nobel Prize in Physiology or Medicine for his contributions to the discovery of the hepatitis C virus. Dr. Alter is a Senior Scholar at the NIH Clinical Center's Department of Transfusion Medicine and shares the award with Michael Houghton, Ph.D., University of Alberta, Canada, and Charles M. Rice, Ph.D., Rockefeller University, New York City.
Harold Gunson Fellowship
The Harold Gunson Fellowship gives doctors and scientists an opportunity to attend ISBT congresses. A limited number of grants will be made available for ISBT Regional and International congresses. To apply for the fellowship you should:
- Be 40 years of age or under at the date of the first day of the congress.
- Be the first, submitting and presenting author of an abstract which has been accepted for the scientific programme.
- Not have received a Harold Gunson fellowship twice before. Applicants from very high or high HDI countries can only receive the Harold Gunson Fellowship once.
Submit an abstract for the congress and apply for the fellowship here.
Vox Sanguinis Best Paper Prize
The Vox Sanguinis Best Paper Prize is a scientific award for the best original paper that has been published in ISBT’s journal Vox Sanguinis in the previous calendar year. The editors of Vox Sanguinis will compile a list of papers that qualify for this Prize. The value of the prize is €5000 and is granted by the Standing Committee on Vox Sanguinis and the Editorial Board.
Vox Sanguinis Best Paper Prize Winners
